Chapters
| Status | Drug name | NICE TAs | Comments |
|---|---|---|---|
 | Alogliptin (Vipidia®) | 1st line choice | |
| Canagliflozin | ||
 | Continous glucose monitoring system (Dexcom ONE®) | ||
| Dapagliflozin | For treating Type 2 diabetes in line with NICE | |
| Dapagliflozin (Forxiga®) | ||
| Dapagliflozin | ||
 | Dapagliflozin | Specialist centres only for treating Type 1 diabetes | |
| Dulaglutide (Trulicity®) | Not for monotherapy. Not in combination with insulin. | |
| Empagliflozin | ||
| Empagliflozin (Jardiance®) | ||
| Empaglifozin | ||
| Empaglifozin | ||
| Ertugliflozin (Steglatro®) | ||
| Exenatide prolonged release injection (Bydureon®) | ||
| Flash glucose monitoring system (FreeStyle Libre 2®, FreeStyle Libre®) | ||
| Glibenclamide tablets | For patients who do not want to move to insulin but not responding to metformin | |
| Glicazide M/R tablets | 2nd line option | |
| Glicazide tablets | ||
| Glimepiride tablets | ||
| Glucagon hypokit | ||
| Glucose 40% oral gel | ||
| Insulin actrapid® injection (10ml) | Prescribe by brand name | |
| Insulin aspart (Fiasp®) | Prescribe by brand name. For specialist use in pregnancy. | |
| Insulin aspart (Novorapid®) injection | Prescribe by brand name | |
| Insulin degludec 100 units/ml (Tresiba®) | Amber for type 1 diabetes- specialist initiation. RICaD. Red for Type 2 diabetes. | |
| Insulin degludec 100 units/ml (Tresiba®) | Amber for type 1 diabetes- specialist initiation. RICaD. Red for Type 2 diabetes. | |
| Insulin detemir (Levemir®) | Prescribe by brand name | |
| Insulin glargene 300 units/ml (Toujeo®) | Specialist initiation. For patients who require more than 80 units of insulin glargine per day and who are troubled by nocturnal hypos. Transfer to Primary Care should not happen until specialists can demonstrate reduction in nocturnal hypos (e.g. after 3–4 months). RICaD. | |
| Insulin glargine (lantus®) | Extremely high relative cost. Prescribe by brand name. | |
| Insulin glargine 100 units/ml (Abasalgar®) | Prescribe by brand name. First line for new patients initiated on insulin glargine 100 units/ml. | |
| Insulin glulisine (Apidra) | Prescribe by brand name | |
| Insulin humalog® mix 25 | Prescribe by brand name | |
| Insulin humalog® mix 50 | Prescribe by brand name | |
| Insulin humulin I® injection | Prescribe by brand name | |
| Insulin humulin S® injection | Prescribe by brand name | |
| Insulin humulin® M3 injection | Prescribe by brand name | |
| Insulin hypurin® bovine isophane injection | For existing patients only | |
| Insulin hypurin® bovine lente injection | For existing patients only | |
| Insulin hypurin® bovine neutral injection | For existing patients only | |
| Insulin hypurin® bovine protamine zinc injection | For existing patients only | |
| Insulin hypurin® porcine 30/70 injection | For existing patients only | |
| Insulin hypurin® porcine isophane injection | For existing patients only | |
| Insulin hypurin® porcine neutral inj (10ml) | For existing patients only | |
| Insulin insulatard® injection | Prescribe by brand name | |
| Insulin insuman® basal | Prescribe by brand name | |
| Insulin insuman® comb 15 injection | Prescribe by brand name | |
| Insulin insuman® comb 25 injection | Prescribe by brand name | |
| Insulin insuman® comb 50 injection | Prescribe by brand name | |
| Insulin insuman® rapid injection | Prescribe by brand name | |
| Insulin lispro 100 units/ml (Humalog®) injection | Prescribe by brand name | |
| Insulin novomix® 30 injection | Prescribe by brand name | |
| IV fluids | Hospital only | |
| Linagliptin tablets | ||
| Liraglutide (Saxenda®) (GLP1s should all be prescribed by brand name) | The use of Liraglutide for this indication is restricted to prescribing in secondary care by a specialist multidisciplinary Tier 3 weight management service with a commercial agreement in place. Prescribe by brand (Saxenda®) to avoid patients inadvertently receiving a different product licensed for type 2 diabetes. | |
| Liraglutide (Victoza®) injection (GLP1s should all be prescribed by brand name) | THIS IS FOR DIABETES ONLY. Prescribe by brand (Victoza®) to avoid patients inadvertently receiving a different product licensed for obesity. 1.8 mg is non-formulary. | |
| Lixisenatide (Lyxumia®) | 1st line choice GLP1 for co-prescribing with insulin. RICaD. | |
| Metformin liquid | ||
| Metformin M/R tablets | 2nd line - only for patients intolerant of slowly titrated standard release metformin. Sukkarto SR 500mg and 1000mg. | |
| Metformin tablets | ||
| Pioglitazone tablets | ||
| Repaglinide tablets | ||
| Semaglutide (Wegovy®) | The use of semaglutide for this indication is restricted to prescribing in secondary care by a specialist multidisciplinary Tier 3 weight management service with a commercial agreement in place. Prescribe by brand (Wegovy®) to avoid patients inadvertently receiving a different product licensed for type 2 diabetes. The Wegovy® brand of semaglutide is not commercially available yet. | |
| Semaglutide solution for injection (Ozempic®) | ||
| Semaglutide tablets (Rybelsus®) (GLP1s should all be prescribed by brand name) | ||
| Sitagliptin tablets | ||
| Soluble insulin | Hospital only | |
| Tirzepatide (Mounjaro®) |
Drug status key
Formulary drugs are allocated a traffic light status. This provides guidance on where clinical and prescribing responsibilities lie in regard to the initiation and maintenance of prescribing.
Grey
Positive NICE TA and/or awaiting local clarification on place in therapy. Please contact your medicines optimisation team for more information.
Red
Initiation and maintenance of prescribing by specialists only.
Amber
Initiation and maintenance of prescribing by specialists and transfer to primary care prescribing when appropriate, or in primary care following a specialists recommendation. Prior to initiation some medicines may require committee agreement or a framework to support safe transfer and maintenance.
Green
Initiation and maintenance of prescribing by specialists, GPs and other qualified clinicians.
Blue
Under review at University Hospitals Birmingham NHS Foundation Trust.
